Eckert & Ziegler

What Eckert & Ziegler does

Eckert & Ziegler SE is a Berlin-headquartered, TecDAX-listed (Deutsche Börse, ISIN DE0005659700) isotope technology group operating across medical, scientific, and industrial end-markets. The company's core capabilities span the radioisotope value chain — production of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, and Yttrium-90, alongside brachytherapy implants (I-125 prostate and ophthalmic seeds, Ru-106 eye applicators) and industrial radiometry products (Kr-85 thickness sources, Ni-63 detection sources, calibration sources). Its technology platform centers on a dedicated Alpha Laboratory in Berlin for Actinium-225, the proprietary GalliaPharm Ge-68/Ga-68 generator system, GMP-compliant radiopharmaceutical manufacturing suites, the Modular-Lab PharmTracer synthesis platform, and cyclotron-based production at the Berlin-Buch, Braunschweig, and Jintan (China, via 50:50 JV QKM with DC Pharma) sites.

The business generates revenue through three primary streams: (i) one-time sales of isotope products to pharmaceutical companies, hospitals, and research institutions; (ii) contract development and manufacturing (CDMO) services for radiopharmaceuticals, supplied under quote-based B2B contracts to clients including Molecular Partners, SK Biopharmaceuticals, Ariceum, Bicycle Therapeutics, Telix, and PentixaPharm; and (iii) hardware sales of brachytherapy devices and industrial radiometry products. Go-to-market is enterprise field sales complemented by industry engagement such as the annual Boston Radionuclide Theranostics Forum. The customer base is horizontally segmented into pharmaceutical/biotech companies (primary), nuclear medicine departments and hospitals (primary), radiation oncology centers, and industrial/scientific institutions.

Recent strategic posture is offensive: opening the China QKM production facility in June 2026, launching commercial Ac-225 production in December 2024, spinning off PentixaPharm as a separate listed entity in October 2024, signing multiple supply and development agreements (Molecular Partners, SK Biopharmaceuticals, Bicycle Therapeutics, Actinium Pharmaceuticals, AtomVie, Archeus), and converting from AG to SE legal form in March 2024. Headcount exceeds 1,000 across Germany, the US, China, Brazil, and additional markets, with multi-year Deloitte Best Managed Companies recognition (2024-2026) and consecutive German vocational training quality awards.

Name

Eckert & Ziegler

Legal name

Eckert & Ziegler SE

Website

https://ezag.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Eckert & Ziegler SE is a Berlin-based, TecDAX-listed isotope technology group producing medical radioisotopes (Ge-68/Ga-68, Lu-177, Ac-225, Y-90), brachytherapy implants, and radiopharmaceutical CDMO services for pharmaceutical, biotech, hospital, and industrial customers across Europe, the Americas, and Asia.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals and Medical Isotopes

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833), Industrial Inorganic Chemicals (2810), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.) (EUAKAIAB)

Keywords

• Medical isotope production
• Radiopharmaceutical CDMO services
• Brachytherapy seeds
• Nuclear medicine imaging
• Industrial radiometry sources

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Infrastructure, Personnel, Marketing or Sales

Revenue model

1. Isotope Product Sales: Sale of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125, Ruthenium-106, and Krypton-85 to pharmaceutical companies, hospitals, and research institutions for diagnostics and therapy.
2. Radiopharmaceutical CDMO Services: Contract development and manufacturing of radiopharmaceutical products for clinical trials and commercial production, serving pharmaceutical partners across the globe. Includes GMP manufacturing suites and synthesis equipment such as Modular-Lab PharmTracer.
3. Radiotherapy Devices and Implants: Sale of brachytherapy seeds (I-125 for prostate cancer, Ru-106 for eye cancer), SagiNova tumor irradiation devices, and associated applicators for cancer treatment.
4. Industrial Radiometry Products: Supply of isotope-based industrial measurement and calibration products including Krypton-85 sources for thickness measurement and Nickel-63 sources for explosive/drug detection, as well as calibration sources for radioactivity measurement instruments.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Eckert & Ziegler manufactures and supplies medical isotopes (Germanium-68/Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125) and brachytherapy products (prostate and ophthalmic seeds, Ru-106 eye applicators) for cancer therapy and diagnostics, and provides contract development and manufacturing (CDMO) services for radiopharmaceuticals. The company also produces industrial radiometry sources (Krypton-85, Nickel-63) and calibration sources for measurement, detection, and security applications.

Product overview

Eckert & Ziegler operates two main business segments: Medical (Radiopharma) and Isotope Products. The Medical segment encompasses radiopharmaceutical products and CDMO services, including GalliaPharm® Ge-68/Ga-68 generators, therapeutic isotopes (Lutetium-177, Actinium-225, Yttrium-90), and brachytherapy seeds (I-125 for prostate and eye cancer, Ru-106 eye applicators). The Isotope Products segment covers industrial radiometry applications including Krypton-85 for thickness measurement, Nickel-63 for security detection, and calibration sources. The company provides GMP manufacturing services for clinical trials and commercial radiopharmaceutical production across its global facilities in Germany, with recent expansion to China via the Qi Kang Medical Technology joint venture.

Differentiator

Problem solved

Functional benefit

Brands

• GalliaPharm: Ge-68/Ga-68 radionuclide generator product line for PET diagnostics
• Theralugand
• Modular-Lab PharmTracer

Products and services

• GalliaPharm Ge-68/Ga-68 Radionuclide Generator Radioisotope generator producing Gallium-68 (Ga-68) for PET diagnostic imaging in nuclear medicine, including prostate cancer and neuroendocrine tumor diagnostics. Produced at the Berlin-Buch campus under GMP conditions.
• Lutetium-177 Therapeutic beta-emitting radioisotope supplied in GMP quality for targeted radioligand therapies including neuroendocrine tumors and prostate cancer. Includes the Theralugand product with European approval.
• Actinium-225 Alpha-emitting radioisotope used in targeted alpha therapy for next-generation cancer treatments, with production capabilities in Berlin and via the QKM joint venture in China.
• Yttrium-90
• I-125 Prostate Seeds Radioactive iodine-125 seeds used for brachytherapy treatment of prostate cancer. Holds MDR certification for the European market.
• I-125 Ophthalmic Seeds Radioactive iodine-125 seeds and COMS applicators for the treatment of eye cancers, particularly uveal melanoma.
• Ruthenium-106 Eye Applicators Beta-emitting ruthenium-106 applicators used in brachytherapy for the treatment of eye tumors, maintained through MDR certification.
• Modular-Lab PharmTracer Cassette-based synthesis device used by radiopharmaceutical manufacturing facilities to produce radioactively labeled compounds for clinical and commercial use.
• Krypton-85 Industrial Sources Industrial isotope products using Krypton-85 for thickness measurement applications in manufacturing processes such as paper and metal production.
• Nickel-63 Detection Sources Radioactive nickel-63 sources used in security industry applications including explosive detection and drug detection equipment.
• Calibration Sources Calibration sources used to verify and validate radioactivity measurement devices in radiation protection, environmental monitoring, and laboratory settings.
• Radiopharmaceutical CDMO Services Contract development and manufacturing organization (CDMO) services providing GMP manufacturing suites and capabilities for radiopharmaceutical clinical trial material and commercial production, including the production line for Modular-Lab PharmTracer synthesis devices.

Quantifiable outcome

• 29% dividend increase from EUR 0.17 to EUR 0.22 per share for fiscal year 2025
• +3 more outcomes

Named customers15 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered core and minor.

• DongCheng Pharma (DC Pharma) / Qi Kang Medical Technology (QKM)coreStrategic or Co-development Partner · 11 June 2026Parity 50:50 joint venture Qi Kang Medical Technology (QKM) for production of medical isotopes in China. Located in Jintan district, Changzhou, with 9,500 m² facility. Phase 1 produces Ge-68 (mother isotope for Ga-68); Phase 2 plans first commercial Ac-225 production in China. Eckert & Ziegler contributes isotope production expertise; DC Pharma provides market access and regulatory knowledge in China.
• Thor MedicalminorStrategic or Co-development Partner · 28 May 2026Partnership announced on May 28, 2026, to expand production capabilities or technology access in the radiopharmaceutical sector.
• Morrison Foerster (Legal Counsel)minorOthers · 28 May 2026Morrison Foerster served as the organizer of the 4th Boston Radionuclide Theranostics Forum in 2026.
• Solomon Partners (Sponsor)minorOthers · 28 May 2026Solomon Partners sponsored the 4th Boston Radionuclide Theranostics Forum organized by Eckert & Ziegler.
• German American Business Council of BostonminorOthers · 28 May 2026German American Business Council of Boston provided organizational support for the 4th Boston Radionuclide Theranostics Forum.
• Molecular Partners AGcoreStrategic or Co-development Partner · 26 February 2026Development agreement for Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides manufacturing services from its facilities including the Alpha Laboratory in Berlin dedicated to alpha emitters. Partnership supports Molecular Partners' lead candidate MP0712 in Phase 1/2a trials for small cell lung cancer.
• SK Biopharmaceuticals Co., Ltd.coreTechnology or Integration · 3 December 2025Supply agreement for Actinium-225 (Ac-225), a critical isotope used in cancer therapies. This establishes a European supply base for SK, diversifying its supply network previously reliant on North American sources and ensuring stability amid limited global production.
• ArcheusminorChannel Partner/ Reseller/ Distributor · 29 July 2025Eckert & Ziegler serves as US manufacturer for Archeus' next-generation radiopharmaceutical, expanding its role as a CDMO partner in the US market.
• PentixaPharm AGcoreStrategic or Co-development Partner · 24 April 2025Manufacturing agreement for Yttrium-90-based PentixaTher radiopharmaceutical. Eckert & Ziegler holds majority stake in PentixaPharm, which was spun off as a separate listed entity and is developing CXCR4-targeted radiopharmaceuticals for hematologic malignancies and solid tumors.
• Actinium PharmaceuticalscoreTechnology or Integration · 25 March 2025Supply of Actinium-225 for Actinium Pharmaceuticals' comprehensive clinical program in targeted alpha therapy for various cancers.
• AtomVie Global RadiopharmacoreChannel Partner/ Reseller/ Distributor · 20 March 2025Worldwide agreement for radiopharmaceutical manufacturing and supply services, expanding Eckert & Ziegler's CDMO footprint globally.
• Bicycle TherapeuticscoreStrategic or Co-development Partner · 27 February 2025Strategic partnership for development and manufacturing of Bicycle Radioconjugates using therapeutic radioisotopes. Eckert & Ziegler provides manufacturing capabilities for radiolabeling of Bicycle's targeted radiotherapy candidates.
• Ariceum Therapeutics GmbHcoreTechnology or Integration · 5 December 2024Global supply agreement for medical isotopes supporting Ariceum's PSMA-targeted diagnostic and therapeutic radiopharmaceutical programs for cancer. Ariceum acquired Theragnostics Ltd in June 2023 to strengthen its PSMA kit portfolio.
• Telix PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 13 November 2024Cooperation and license agreement for Illuccix PSMA-PET diagnostics. Eckert & Ziegler supports manufacturing and distribution of the diagnostic kit in Germany, leveraging its radiopharmaceutical CDMO capabilities and regulatory approvals in the German market.
• UJF (Ústav jaderné fyziky AV ČR)coreStrategic or Co-development Partner · 19 June 2024Partnership to significantly increase Actinium-225 production volume. The new production facility opened in June 2024 and represents a major expansion of alpha emitter manufacturing capacity in Europe, with UJF contributing research infrastructure and Eckert & Ziegler providing commercial production capabilities.
• Nucleus RadiopharmacoreTechnology or Integration · 31 January 2024Supply agreement for therapeutic radioisotopes including Lutetium-177 for Nucleus Radiopharma's radiopharmaceutical development pipeline.

Scale indicators9 records

Recent moves12 records

Expansion highlights7 records

Others

• Cardinal Health (Radiopharmaceutical Distribution): Cardinal Health operates a nuclear pharmacy services network distributing radiopharmaceuticals to US hospitals. While not a direct manufacturer, it operates in the same nuclear medicine distribution channel that E&Z supplies into, making it a channel-adjacent peer.

Broad incumbents

• GE HealthCare: GE HealthCare operates a large radiopharmacy network (PETNET) and supplies imaging agents including Ga-68 generators, plus broader imaging equipment. It overlaps with E&Z in nuclear medicine imaging supply but operates at far broader scale across the imaging value chain.
• Bayer (Radiology / Curium JV): Bayer's radiology business (legacy Medrad/Mallinckrodt) develops contrast and radiopharmaceutical agents including Xofigo (Ra-223). As a major life sciences player it competes broadly with E&Z in alpha-emitting therapeutics and nuclear medicine.

Direct peers

• Lantheus Holdings: Lantheus is a US-based radiopharmaceutical-focused company with diagnostic imaging products (e.g., Pylarify PSMA-PET). It overlaps with E&Z's diagnostic radiopharma franchise and competes for nuclear medicine supply contracts.
• Curium Pharma: Curium is one of the world's largest nuclear medicine companies producing diagnostic and therapeutic radiopharmaceuticals (Mo-99/Tc-99m, I-131, Lu-177). It directly overlaps E&Z's radiopharma CDMO and isotope production business across nuclear medicine customers.
• ITM Isotope Technologies Munich: ITM is a German radiopharmaceutical company producing high-purity Lu-177 and other medical isotopes for cancer therapy. It directly competes with E&Z in Lu-177 supply and is also developing Ac-225 - a head-to-head competitor in the same geography.
• Telix Pharmaceuticals: Telix develops and commercializes therapeutic and diagnostic radiopharmaceuticals (Illuccix PSMA-PET). The firm is both an E&Z customer (manufacturing/distribution deal in Germany) and a direct competitor in commercial radiopharmaceutical products.

Emerging players

• Nucleus Radiopharma: Nucleus Radiopharma is a US-based CDMO building dedicated radiopharmaceutical manufacturing capacity, including Lu-177. It is both an E&Z customer (Lu-177 supply) and an emerging competitor in CDMO services.
• NorthStar Medical Radioisotopes: NorthStar produces Mo-99 domestically in the US without relying on legacy reactor sources, expanding into Cu-64, Cu-67, and other therapeutic isotopes. It is an emerging competitor in isotope production where E&Z also participates.
• AtomVie Global Radiopharma: AtomVie is a Canadian radiopharmaceutical CDMO spun out from the Centre for Probe Development and Commercialization, offering GMP manufacturing for radiopharmaceuticals. It is both an E&Z partner (worldwide supply agreement) and an emerging CDMO competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eckert-&-ziegler-ag
• Xx.com/bebig_group
• Facebookfacebook.com/profile.php

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eckert & Ziegler